Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

59.88
-0.4800-0.80%
Post-market: 59.880.00000.00%19:30 EDT
Volume:1.87M
Turnover:112.59M
Market Cap:9.95B
PE:-17.21
High:60.99
Open:60.37
Low:59.78
Close:60.36
52wk High:86.74
52wk Low:49.13
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.93
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:22.63
PE(LYR):-25.15

Loading ...

Corrected-Ionis Pharmaceuticals Q1 Revenue USD 246 Million VS. Ibes Estimate USD 195.6 Million (Corrects Amount)

THOMSON REUTERS
·
Apr 29

Ionis partner GSK announces bepirovirsen NDA accepted for priority review

TIPRANKS
·
Apr 28

Ionis partner GSK’s bepirovirsen wins FDA Priority Review for hepatitis B NDA

Reuters
·
Apr 28

Ionis Pharmaceuticals Inc: Pdufa Date of October 26, 2026

THOMSON REUTERS
·
Apr 28

Ionis Partner GSK Announces Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by U.S. FDA as a Potential First-in-Class Medicine for Chronic Hepatitis B

THOMSON REUTERS
·
Apr 28

Ionis Pharmaceuticals price target lowered to $108 from $110 at TD Cowen

TIPRANKS
·
Apr 23

Earning Preview: Ionis Pharmaceuticals Q1 revenue is expected to increase by 56%, and institutional views are bullish

Earnings Agent
·
Apr 23

How Zilganersen’s Positive Pivotal Data and FDA Priority Review Could Impact Ionis Pharmaceuticals (IONS) Investors

Simply Wall St.
·
Apr 23

H.C. Wainwright Remains a Buy on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Apr 22

Ionis Pharmaceuticals Initiated at Buy by Canaccord Genuity

Dow Jones
·
Apr 21

Ionis Pharmaceuticals price target raised to $130 from $95 at Morgan Stanley

TIPRANKS
·
Apr 21

Ionis Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Apr 21

This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. -- Barrons.com

Dow Jones
·
Apr 21

Ionis announces additional results from zilganersen study in AxD

TIPRANKS
·
Apr 21

BRIEF-Ionis Pharmaceuticals Inc - Zilganersen 50 Mg Meets Primary Endpoint, Stabilizes Gait Speed In Patients ≥5 Years At Week 61

Reuters
·
Apr 21

Canaccord Genuity Initiates Coverage on Ionis Pharmaceuticals With Buy Rating, $110 Price Target

MT Newswires Live
·
Apr 21

Ionis Pharmaceuticals Inc - Zilganersen Under FDA Priority Review With Pdufa Date Set for September 22, 2026

THOMSON REUTERS
·
Apr 21

Ionis Pharmaceuticals Inc - Key Secondary Endpoint Results Consistently Favored Zilganersen Over Control

THOMSON REUTERS
·
Apr 21

Ionis says zilganersen trial in Alexander disease meets primary endpoint on gait speed

Reuters
·
Apr 21